Unlike many unprofitable biotech companies, Regeneron was in the “green” and generated $4.3 billion in net income in 2022. Vertex Pharmaceuticals is a biotech company focused on developing ...

The oft-cited silver lining in this market has been the ... The vicissitudes of the market often depress public biotech prices such that even a hard-to-refuse 100% price premium does not generate ...

The silver lining is that certain states are investing in innovation ... but I think the campaign was pretty light on ...

Fidelity Advisor Biotechnology Fund earns an Above Average ... leading to its Morningstar Medalist Rating of Silver.

But one of the most powerful aspiring entrants, Novo Nordisk, may not be as intimidating for the biotech as it once was. Novo's molecule semaglutide (commonly known by the trade names Ozempic and ...

Biotech stocks are in the eye of the storm as the world recovers from the global pandemic. Government institutions and professional traders are banking on biotech stocks to continually develop a ...

If I had to buy one share of any biotech with no price restriction, I'd naturally gravitate toward the most successful companies in the industry. However, the exercise becomes more complicated if ...

Real-time index price for PHLX Gold/Silver Index (XAU), along with buy or sell indicators, analysis, charts, historical ...

Genscript Biotech (HK:1548) has released an update. Genscript Biotech has announced the deconsolidation of its subsidiary, Legend Biotech, following changes to their deposit agreement. This ...

Legend Biotech (LEGN) has released an update. Legend Biotech Corporation held its annual general meeting on October 21, 2024, where shareholders approved key resolutions, including the re-election ...

The analysts might have been a bit too bullish on Vir Biotechnology, Inc. ( NASDAQ:VIR ), given that the company ...

The biotech is reviewing the data before deciding ... with IPOs north of $100M each The available evidence is light on silver linings. In a note to investors, William Blair analysts said Alto ...